Pilar Puig-Serra

Dr. Pilar Puig-Serra

Spanish National Cancer Research Centre (CNIO)
orcid
Postdoctoral Researcher

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
MMMarta Martinez-Lage
Marta Martinez-Lage
RTRaul Torres-Ruiz
Raul Torres-Ruiz
PPPilar Puig-Serra
Pilar Puig-Serra
PMP. Moreno-Gaona
P. Moreno-Gaona
MMM. C. Martin
M. C. Martin
SRSandra Rodriguez-Perales
Sandra Rodriguez-Perales
Fusion oncogenes (FOs) are common in many cancer types and are powerful drivers of tumor development. Because their expression is exclusive to cancer cells and their elimination induces cell apoptosis in FO-driven cancers, FOs are attractive therapeutic targets. However, specifically targeting the resulting chimeric products is challenging. Based on CRISPR/Cas9 technology, here we devise a simple, efficient and non-patient-specific gene-editing strategy through targeting of two introns of the genes involved in the rearrangement, allowing for robust disruption of the FO specifically in cancer cells. As a proof-of-concept of its potential, we demonstrate the efficacy of intron-based targeting of transcription factors or tyrosine kinase FOs in reducing tumor burden/mortality in in vivo models. The FO targeting approach presented here might open new horizons for the selective elimination of cancer cells.

12 November 2018 in Biomedicines
Verified
Journal Article
Open access
PDF file
MMMarta Martinez-Lage
Marta Martinez-Lage
PPPilar Puig-Serra
Pilar Puig-Serra
PMPablo Menendez
Pablo Menendez
RTRaul Torres-Ruiz
Raul Torres-Ruiz
SRSandra Rodriguez-Perales
Sandra Rodriguez-Perales
Cancer is the second leading cause of death globally and remains a major economic and social burden. Although our understanding of cancer at the molecular level continues to improve, more effort is needed to develop new therapeutic tools and approaches exploiting these advances. Because of its high efficiency and accuracy, the CRISPR-Cas9 genome editing technique has recently emerged as a potentially powerful tool in the arsenal of cancer therapy. Among its many applications, CRISPR-Cas9 has shown an unprecedented clinical potential to discover novel targets for cancer therapy and to dissect chemical-genetic interactions, providing insight into how tumours respond to drug treatment. Moreover, CRISPR-Cas9 can be employed to rapidly engineer immune cells and oncolytic viruses for cancer immunotherapeutic applications. Perhaps more importantly, the ability of CRISPR-Cas9 to accurately edit genes, not only in cell culture models and model organisms but also in humans, allows its use in therapeutic explorations. In this review, we discuss important considerations for the use of CRISPR/Cas9 in therapeutic settings and major challenges that will need to be addressed prior to its clinical translation for a complex and polygenic disease such as cancer.

Verified
Journal Article
Open access
PDF file
PPPilar Puig-Serra
Pilar Puig-Serra
MCMaria Cruz Casado-Rosas
Maria Cruz Casado-Rosas
MMMarta Martinez-Lage
Marta Martinez-Lage
Beatriz Olalla-SastreBeatriz Olalla-Sastre
Beatriz Olalla-Sastre
AAAlejandro Alonso-Yanez
Alejandro Alonso-Yanez
SRSandra Rodriguez-Perales
Sandra Rodriguez-Perales
CRISPR/Cas is a prokaryotic self-defense system, widely known for its use as a gene-editing tool. Because of their high specificity to detect DNA and RNA sequences, different CRISPR systems have been adapted for nucleic acid detection. CRISPR detection technologies differ highly among them, since they are based on four of the six major subtypes of CRISPR systems. In just 5 years, the CRISPR diagnostic field has rapidly expanded, growing from a set of specific molecular biology discoveries to multiple FDA-authorized COVID-19 tests and the establishment of several companies. CRISPR-based detection methods are coupled with pre-existing preamplification and readout technologies, achieving sensitivity and reproducibility comparable to the current gold standard nucleic acid detection methods. Moreover, they are very versatile, can be easily implemented to detect emerging pathogens and new clinically relevant mutations, and offer multiplexing capability. The advantages of the CRISPR-based diagnostic approaches are a short sample-to-answer time and no requirement of laboratory settings; they are also much more affordable than current nucleic acid detection procedures. In this review, we summarize the applications and development trends of the CRISPR/Cas13 system in the identification of particular pathogens and mutations and discuss the challenges and future prospects of CRISPR-based diagnostic platforms in biomedicine.

Verified
Journal Article
Open access
PDF file
IAIrina Palacin Aliana
Irina Palacin Aliana
NGNoemi Garcia
Noemi Garcia
PCPepa Carrion-Navarro
Pepa Carrion-Navarro
PPPilar Puig-Serra
Pilar Puig-Serra
RTRaul Torres-Ruiz
Raul Torres-Ruiz
ÁAÁngel Ayuso-Sacido
Ángel Ayuso-Sacido
The isolation of circulating tumoral DNA (ctDNA) present in the bloodstream brings about the opportunity to detect genomic aberrations from the tumor of origin. However, the low amounts of ctDNA present in liquid biopsy samples makes the development of highly sensitive techniques necessary to detect targetable mutations for the diagnosis, prognosis, and monitoring of cancer patients. Here, we employ standard genomic DNA (gDNA) and eight liquid biopsy samples from different cancer patients to examine the newly described CRISPR-Cas13a-based technology in the detection of the BRAF p.V600E actionable point mutation and appraise its diagnostic capacity with two PCR-based techniques: quantitative Real-Time PCR (qPCR) and droplet digital PCR (ddPCR). Regardless of its lower specificity compared to the qPCR and ddPCR techniques, the CRISPR-Cas13a-guided complex was able to detect inputs as low as 10 pM. Even though the PCR-based techniques have similar target limits of detection (LoDs), only the ddPCR achieved a 0.1% variant allele frequency (VAF) detection with elevated reproducibility, thus standing out as the most powerful and suitable tool for clinical diagnosis purposes. Our results also demonstrate how the CRISPR-Cas13a can detect low amounts of the target of interest, but its base-pair specificity failed in the detection of actionable point mutations at a low VAF; therefore, the ddPCR is still the most powerful and suitable technique for these purposes.

Verified
Journal Article
Open access
PDF file
María Ortiz-Bueno BuenoMaría Ortiz-Bueno Bueno
María Ortiz-Bueno Bueno
Federica ZinghirinoFederica Zinghirino
Federica Zinghirino
PPPilar Puig-Serra
Pilar Puig-Serra
KPKyriaki Paschoudi
Kyriaki Paschoudi
LMLluis Montoliu
Lluis Montoliu
karim benabdellahkarim benabdellah
karim benabdellah
Genome editing (GE) has transformed medicine by allowing precise changes to DNA, offering potential treatments for a range of inherited and acquired disorders. Several technologies support these advances, including zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeats (CRISPR)-based systems, of which the latter has emerged as the most accessible, versatile, and popular. While GE holds great promise, its clinical use requires careful attention to safety, ethics and regulatory standards. Inadvertent on- and off-target DNA alterations and unintended modification of non-target cells pose major technical challenges, while bioethical considerations and the need for harmonized safety standards create regulatory challenges. The Food and Drug Administration (FDA) and European Medicines Agency (EMA), as regulatory agencies for key advanced therapy markets, provide detailed guidance on these aspects, emphasizing rigorous preclinical testing, patient monitoring, ethical consent, and compliance with legal frameworks. This concise review summarizes what is currently published in the scientific literature and recommended by regulatory agencies, providing an overview of the responsible clinical application of GE, with emphasis on patient safety, adherence to regulatory guidance, and ethical practice.

22 December 2025 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
ANA. Nieto-Sanchez
A. Nieto-Sanchez
MMMarta Martinez-Lage
Marta Martinez-Lage
PPPilar Puig-Serra
Pilar Puig-Serra
SCS. Carpintero
S. Carpintero
AAA. Alonso-Yanez
A. Alonso-Yanez
SRSandra Rodriguez-Perales
Sandra Rodriguez-Perales
Oncogene amplifications fuel some of the most lethal, therapy‑refractory cancers, yet remain clinically untargeted. We report a single‑guide CR